Raymond James Financial Services Advisors Inc. boosted its position in shares of bluebird bio Inc (NASDAQ:BLUE) by 41.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,117 shares of the biotechnology company’s stock after purchasing an additional 915 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in bluebird bio were worth $555,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also recently made changes to their positions in the company. Meeder Asset Management Inc. increased its stake in shares of bluebird bio by 2,110.3% in the 4th quarter. Meeder Asset Management Inc. now owns 641 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 612 shares during the last quarter. NuWave Investment Management LLC bought a new stake in shares of bluebird bio in the 4th quarter valued at about $135,000. Ladenburg Thalmann Financial Services Inc. increased its stake in shares of bluebird bio by 454.2% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock valued at $136,000 after acquiring an additional 813 shares during the last quarter. Biondo Investment Advisors LLC acquired a new position in shares of bluebird bio in the 3rd quarter valued at approximately $203,000. Finally, D.A. Davidson & CO. acquired a new position in shares of bluebird bio in the 4th quarter valued at approximately $214,000.
Several equities analysts recently issued reports on BLUE shares. Cantor Fitzgerald set a $113.00 price objective on bluebird bio and gave the company an “underweight” rating in a research report on Monday, December 11th. Jefferies Group raised bluebird bio from a “hold” rating to a “buy” rating and upped their price target for the stock from $130.00 to $211.00 in a research report on Monday, December 11th. BMO Capital Markets set a $215.00 price target on bluebird bio and gave the stock a “buy” rating in a research report on Monday, December 11th. Wells Fargo reaffirmed an “outperform” rating and set a $242.00 price target (up previously from $190.00) on shares of bluebird bio in a research report on Tuesday, December 12th. Finally, SunTrust Banks increased their price objective on bluebird bio to $223.00 and gave the company a “buy” rating in a report on Tuesday, December 12th. Four equities research analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have assigned a buy rating to the company’s stock. bluebird bio presently has a consensus rating of “Hold” and a consensus price target of $195.20.
BLUE stock traded down $7.45 during trading hours on Friday, hitting $162.70. 1,089,011 shares of the stock were exchanged, compared to its average volume of 934,688. The stock has a market capitalization of $8,504.69, a price-to-earnings ratio of -21.10 and a beta of 2.16. bluebird bio Inc has a 12 month low of $74.45 and a 12 month high of $236.17.
bluebird bio (NASDAQ:BLUE) last released its earnings results on Wednesday, February 21st. The biotechnology company reported ($2.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.68) by ($0.84). The company had revenue of $4.17 million for the quarter, compared to analyst estimates of $7.11 million. bluebird bio had a negative return on equity of 28.09% and a negative net margin of 947.42%. The business’s revenue for the quarter was up 169.0% compared to the same quarter last year. During the same period last year, the company posted ($1.88) earnings per share. equities research analysts expect that bluebird bio Inc will post -8.39 earnings per share for the current fiscal year.
In other news, insider Jason Cole sold 25,000 shares of the stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $195.91, for a total transaction of $4,897,750.00. Following the sale, the insider now directly owns 44,798 shares of the company’s stock, valued at approximately $8,776,376.18. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider David Davidson sold 22,000 shares of the firm’s stock in a transaction dated Monday, April 2nd. The shares were sold at an average price of $167.52, for a total value of $3,685,440.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 80,034 shares of company stock worth $15,122,163. 3.90% of the stock is currently owned by insiders.
WARNING: “Raymond James Financial Services Advisors Inc. Purchases 915 Shares of bluebird bio Inc (NASDAQ:BLUE)” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/raymond-james-financial-services-advisors-inc-raises-holdings-in-bluebird-bio-inc-blue.html.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.